A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy

• Published in: Europace (London, England) Vol. 21; no. 10; pp. 1559 - 1565
• Main Authors: Norrish, Gabrielle, Ding, Tao, Field, Ella, McLeod, Karen, Ilina, Maria, Stuart, Graham, Bhole, Vinay, Uzun, Orhan, Brown, Elspeth, Daubeney, Piers E F, Lota, Amrit, Linter, Katie, Mathur, Sujeev, Bharucha, Tara, Kok, Khoon Li, Adwani, Satish, Jones, Caroline B, Reinhardt, Zdenka, Omar, Rumana Z, Kaski, Juan Pablo
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.10.2019
• Subjects: Adolescent; Cardiology; Cardiomyopathy, Hypertrophic - complications; Cardiomyopathy, Hypertrophic - physiopathology; Child; Child, Preschool; Clinical Research; Death, Sudden, Cardiac - epidemiology; Death, Sudden, Cardiac - etiology; Death, Sudden, Cardiac - prevention & control; Defibrillators, Implantable; Female; Follow-Up Studies; Humans; Incidence; Male; Practice Guidelines as Topic; Retrospective Studies; Risk Assessment - methods; Risk Factors; Societies, Medical; Survival Rate - trends; United Kingdom - epidemiology; United Kingdom; Hypertrophic cardiomyopathy; Risk; Children; ESC Guidelines; Sudden death
• ISSN: 1099-5129; 1532-2092; 1532-2092
• DOI: 10.1093/europace/euz118

Abstract Aims Sudden cardiac death (SCD) is the most common cause of death in children with hypertrophic cardiomyopathy (HCM). The European Society of Cardiology (ESC) recommends consideration of an implantable cardioverter-defibrillator (ICD) if two or more clinical risk factors (RFs) are present, but this approach to risk stratification has not been formally validated. Methods and results Four hundred and eleven paediatric HCM patients were assessed for four clinical RFs in accordance with current ESC recommendations: severe left ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia, and family history of SCD. The primary endpoint was a composite outcome of SCD or an equivalent event (aborted cardiac arrest, appropriate ICD therapy, or sustained ventricular tachycardia), defined as a major arrhythmic cardiac event (MACE). Over a follow-up period of 2890 patient years (median 5.5 years), MACE occurred in 21 patients (7.5%) with 0 RFs, 19 (16.8%) with 1 RFs, and 3 (18.8%) with 2 or more RFs. Corresponding incidence rates were 1.13 [95% confidence interval (CI) 0.7–1.73], 2.07 (95% CI 1.25–3.23), and 2.52 (95% CI 0.53–7.35) per 100 patient years at risk. Patients with two or more RFs did not have a higher incidence of MACE (log-rank test P = 0.34), with a positive and negative predictive value of 19% and 90%, respectively. The C-statistic was 0.62 (95% CI 0.52–0.72) at 5 years. Conclusions The incidence of MACE is higher for patients with increasing numbers of clinical RFs. However, the current ESC guidelines have a low ability to discriminate between high- and low-risk individuals.